Real-World Effectiveness of Sipuleucel-T on Overall Survival in Men with Advanced Prostate Cancer Treated with Androgen Receptor-Targeting Agents

Abstract

Introduction The treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) continues to evolve. Sipuleucel-T was the first immunotherapy approved by the US Food and Drug Administration (FDA) to treat asymptomatic or minimally symptomatic mCRPC. The androgen receptor-targeting agents (ARTAs) abiraterone acetate and enzalutamide were initially approved to treat mCRPC. Looking at chemotherapy-naïve men with mCRPC, we compared survival outcomes between the sipuleucel-T + ARTA cohort (men who received either sipuleucel-T or an ARTA in the first line, and then the other in the second line within 6 months) and the ARTA monotherapy cohort (men who only received ARTA monotherapy). Methods This retrospective cohort analysis used longitudinal, adjudicated claims data from the US Medicare Fee-for-Service 100% research identifiable dataset that includes both urologic and oncologic practice settings. Eligible men started their first mCRPC treatment with either sipuleucel-T or ARTA in either 2014 or 2015 and had continuous Medicare Parts A, B, and D eligibility for the subsequent 3 years. A multivariable Cox proportional hazards regression model was used to analyze overall survival (OS), both overall and by index year, and to control for differences. Results The sipuleucel-T + ARTA and ARTA monotherapy cohorts comprised 773 and 4642 men, respectively, with different characteristics at treatment start. The most commonly used ARTAs were enzalutamide in the former and abiraterone in the latter cohort. Median OS was 30.4 and 14.3 months in the sipuleucel-T + ARTA and ARTA monotherapy cohorts, respectively, with the sipuleucel-T + ARTA cohort having a 28.3% lower risk of death than the ARTA monotherapy cohort (hazard ratio 0.717; 95% CI 0.648, 0.793; p < 0.01). Conclusions This real-world study of mCRPC treatment indicates that men receiving sipuleucel-T and ARTAs had a longer median OS than patients receiving treatment with an ARTA alone, suggesting that leveraging mechanisms of action can be beneficial in treating patients with mCRPC. Supplementary Information The online version contains supplementary material available at 10.1007/s12325-022-02085-6.

Current status of immunological therapies for rheumatoid arthritis with a focus on antigen-specific therapeutic vaccines

“…This open-label phase I trial demonstrated a good safety and biological activity profile for Rheumavax as indicated by an increased ratio of Treg to T effector (Teff) cells and decreases in disease activity score in 28 joints (DAS28) within 1 month in Rheumavax-treated patients ( Table 1 ). Again, although autologous cell therapies have been commercially available for almost a decade ( 43 ), to date, they have not been proven to be economically successful due to the extremely high cost of generating these patient-specific cells.…”

Stand der Forschung und neue therapeutische Perspektiven in der Immuntherapie des Prostatakarzinoms

“…Hinsichtlich der Sicherheit waren die häufigsten unerwünschten Ereignisse in der Sipuleucel-T-Gruppe Kopfschmerzen und Fieber [134]. Derzeit laufen Studien zur Kombination dieses Impfstoffs mit den Zielwirkstoffen AR [136], Atezolizumab [137] oder Radio-223 [138] bei Patienten mit mCRPC. Er ist der einzige von der FDA zugelassene Impfstoff gegen PCa.…”

Therapeutic strategies for gastric cancer targeting immune cells: Future directions

“…DC vaccines have shown OS benefits in solid tumors such as prostate cancer ( 152 ), melanoma ( 153 ), glioblastoma ( 154 ), and ovarian cancer ( 155 ). The studies showed that inactivated tumor cells ( 156 ), tumor lysates ( 153 ), tumor vesicles ( 157 ), synthetic tumor peptides ( 158 ), or synthetic tumor antigen mRNA ( 159 ) all can be used as DC vaccine–loaded antigens.…”